Austin, TX—The American Botanical Council (ABC) has published an updated ingredient-specific monograph summarizing selected scientific and clinical studies of Pycnogenol®, according to a press release.
Pycnogenol® is a patented dietary ingredient derived from French maritime pine bark. The revised monograph describes a total of 63 human clinical trials on Pycnogenol—46 more than were included in the original monograph, published in 2010, the press release says. The studies evaluate its potential benefits for health conditions including type 2 diabetes and hypertension.
The accumulated evidence, according to ABC, suggests that Pycnogenol may have a wide range of potential applications, including the ability to improve blood sugar control in patients with type 2 diabetes and improve endothelial function, the ability of blood vessels to widen through relaxation of the muscular wall of the vessels.
Mark Blumenthal, founder and executive director of ABC, said in the release, “Few proprietary botanical extracts have been subjected to human clinical trials in such a wide range of human health conditions. We acknowledge Horphag Research, the producer of Pycnogenol, for its strong commitment to clinical research on its leading ingredient.”
The release noted that Horphag Research, Geneva, Switzerland, invests around $1.5 million annually in new scientific and clinical research.
Victor Ferrari, CEO of Horphag, said in the release, “The new ABC monograph is the most comprehensive technical document on Pycnogenol to date. It will help tremendously in educating the industry and scientific audience.”
The monograph is published in three parts: a clinical overview, a consumer/patient information sheet, and the full monograph describing the research on Pycnogenol. The monograph was written by Heather S. Oliff, Ph.D., and was formally peer reviewed for accuracy.
The monograph can be accessed here.